BioCentury | Jan 20, 2017
Emerging Company Profile

Aiming for durability

Avrobio Inc. is developing cell therapies that are transduced with lentivirus ex vivo to express therapeutic proteins. The approach could provide long-lasting treatments for patients with monogenic rare diseases or cancer. Data from Phase I...
BC Extra | Aug 2, 2016
Financial News

Cell therapy company Avrobio raises $25M

Avrobio Inc. (Cambridge, Mass.) raised $25 million in a series A round co-led by Atlas Venture, Clarus and SV Life Sciences . Avrobio has two cell therapy candidates in Phase I testing: AVR-01 to treat acute...
BC Week In Review | Feb 22, 2016
Company News

University Health Network, Avrobio deal

Avrobio gained exclusive, worldwide rights to two cell therapy candidates from University Health Network (UHN) to treat acute myelogenous leukemia (AML) and Fabry’s disease. By mid-2016, the newco said it expects to begin Phase I...
BC Extra | Feb 19, 2016
Financial News

Atlas backs newco Avrobio

Avrobio Inc. (Cambridge, Mass.) said it secured an undisclosed amount of seed financing from Atlas Venture and licensed two cell therapy candidates from the University Health Network (Toronto, Ontario) to treat acute myelogenous leukemia (AML)...
Items per page:
1 - 4 of 4